Table 3

Effect of response in WBC count and resistance to HU on survival in 261 patients with PV

HR95% CIP
Age > 65 y 4.1 1.9-9.0 < .001 
Male sex 2.0 1.1-3.6 .03 
Cardiovascular risk factors* 1.8 0.9-3.7 .1 
Hematologic values at diagnosis    
    Hemoglobin > 180 g/L 0.8 0.4-1.6 .6 
    WBC > 10 × 109/L 1.6 0.8-3.4 .2 
    Platelet count > 500 × 109/L 1.0 0.5-1.9 .9 
Thrombosis during follow-up 1.6 0.8-3.2 .1 
Bleeding during follow-up 0.8 0.3-1.9 .6 
No response in WBC† 2.7 1.3-5.4 .007 
Resistance to HU 5.6 2.7-11.9 < .001 
HR95% CIP
Age > 65 y 4.1 1.9-9.0 < .001 
Male sex 2.0 1.1-3.6 .03 
Cardiovascular risk factors* 1.8 0.9-3.7 .1 
Hematologic values at diagnosis    
    Hemoglobin > 180 g/L 0.8 0.4-1.6 .6 
    WBC > 10 × 109/L 1.6 0.8-3.4 .2 
    Platelet count > 500 × 109/L 1.0 0.5-1.9 .9 
Thrombosis during follow-up 1.6 0.8-3.2 .1 
Bleeding during follow-up 0.8 0.3-1.9 .6 
No response in WBC† 2.7 1.3-5.4 .007 
Resistance to HU 5.6 2.7-11.9 < .001 
*

Presence of either diabetes, arterial hypertension, smoking, or hypercholesterolemia.

†

Persistence of WBC count > 10 × 109/L despite treatment with HU.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal